MA51636A - Procédés de génération de produits de til enrichis pour des lymphocytes t spécifiques d'un antigène tumoral - Google Patents

Procédés de génération de produits de til enrichis pour des lymphocytes t spécifiques d'un antigène tumoral

Info

Publication number
MA51636A
MA51636A MA051636A MA51636A MA51636A MA 51636 A MA51636 A MA 51636A MA 051636 A MA051636 A MA 051636A MA 51636 A MA51636 A MA 51636A MA 51636 A MA51636 A MA 51636A
Authority
MA
Morocco
Prior art keywords
methods
tumor antigen
lymphocytes specific
til products
products enriched
Prior art date
Application number
MA051636A
Other languages
English (en)
Inventor
Cecile Chartier-Courtaud
Krit Ritthipichai
Original Assignee
Iovance Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Iovance Biotherapeutics Inc filed Critical Iovance Biotherapeutics Inc
Publication of MA51636A publication Critical patent/MA51636A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/10—Preservation of living parts
    • A01N1/12—Chemical aspects of preservation
    • A01N1/122—Preservation or perfusion media
    • A01N1/125—Freeze protecting agents, e.g. cryoprotectants or osmolarity regulators
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/10—Preservation of living parts
    • A01N1/16—Physical preservation processes
    • A01N1/162—Temperature processes, e.g. following predefined temperature changes over time
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/428—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/57—Skin; melanoma
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2315—Interleukin-15 (IL-15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2321—Interleukin-21 (IL-21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Dentistry (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Environmental Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MA051636A 2018-01-08 2019-01-08 Procédés de génération de produits de til enrichis pour des lymphocytes t spécifiques d'un antigène tumoral MA51636A (fr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201862614887P 2018-01-08 2018-01-08
US201862664034P 2018-04-27 2018-04-27
US201862669319P 2018-05-09 2018-05-09
US201862697921P 2018-07-13 2018-07-13
US201862734868P 2018-09-21 2018-09-21
US201862773715P 2018-11-30 2018-11-30

Publications (1)

Publication Number Publication Date
MA51636A true MA51636A (fr) 2020-11-18

Family

ID=65324542

Family Applications (1)

Application Number Title Priority Date Filing Date
MA051636A MA51636A (fr) 2018-01-08 2019-01-08 Procédés de génération de produits de til enrichis pour des lymphocytes t spécifiques d'un antigène tumoral

Country Status (14)

Country Link
US (1) US12104172B2 (fr)
EP (1) EP3737743A1 (fr)
JP (2) JP2021509586A (fr)
KR (1) KR20200119242A (fr)
CN (2) CN111836887A (fr)
AU (2) AU2019205823C1 (fr)
BR (1) BR112020013848A2 (fr)
CA (1) CA3087771A1 (fr)
IL (1) IL275724A (fr)
MA (1) MA51636A (fr)
MX (1) MX2020007046A (fr)
SG (1) SG11202006541UA (fr)
TW (1) TW201938177A (fr)
WO (1) WO2019136456A1 (fr)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201522097D0 (en) 2015-12-15 2016-01-27 Cellular Therapeutics Ltd Cells
GB201700621D0 (en) 2017-01-13 2017-03-01 Guest Ryan Dominic Method,device and kit for the aseptic isolation,enrichment and stabilsation of cells from mammalian solid tissue
BR112019018915A2 (pt) 2017-03-15 2020-04-14 Pandion Therapeutics Inc imunotolerância direcionada
SG11201909949XA (en) 2017-05-24 2019-11-28 Pandion Therapeutics Inc Targeted immunotolerance
USRE50550E1 (en) 2017-12-06 2025-08-26 Pandion Operations, Inc. IL-2 muteins and uses thereof
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
US10174092B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
US20190284553A1 (en) 2018-03-15 2019-09-19 KSQ Therapeutics, Inc. Gene-regulating compositions and methods for improved immunotherapy
TW202039829A (zh) * 2018-11-05 2020-11-01 美商艾歐凡斯生物治療公司 改善之腫瘤反應性ｔ細胞的選擇
US11739146B2 (en) 2019-05-20 2023-08-29 Pandion Operations, Inc. MAdCAM targeted immunotolerance
US20220288121A1 (en) * 2019-08-29 2022-09-15 Board Of Regents, The University Of Texas System Cell cryopreservation medium
JP2022553389A (ja) * 2019-10-25 2022-12-22 アイオバンス バイオセラピューティクス，インコーポレイテッド 腫瘍浸潤リンパ球の遺伝子編集及び免疫療法におけるその使用
KR20220119439A (ko) 2019-12-20 2022-08-29 인스틸 바이오 유케이 리미티드 종양 침윤 림프구를 분리하기 위한 장치 및 방법 및 그것의 용도
US11981715B2 (en) 2020-02-21 2024-05-14 Pandion Operations, Inc. Tissue targeted immunotolerance with a CD39 effector
WO2021222479A1 (fr) 2020-04-28 2021-11-04 Lyell Immunopharma, Inc. Procédés de culture de cellules
EP4146793A1 (fr) 2020-05-04 2023-03-15 Iovance Biotherapeutics, Inc. Sélection de lymphocytes t réactifs à une tumeur améliorés
EP4146794A1 (fr) 2020-05-04 2023-03-15 Iovance Biotherapeutics, Inc. Procédés de production de lymphocytes infiltrant les tumeurs et leurs utilisations en immunothérapie
CA3202473A1 (fr) * 2020-12-17 2022-06-23 Friedrich Graf Finckenstein Traitement de cancers a l'aide de lymphocytes infiltrant les tumeurs
US20240299540A1 (en) * 2021-02-05 2024-09-12 Iovance Biotherapeutics, Inc. Adjuvant therapy for cancer
WO2022166947A1 (fr) * 2021-02-08 2022-08-11 苏州沙砾生物科技有限公司 Procédé de préparation de lymphocytes infiltrant les tumeurs et leur utilisation
WO2022204564A2 (fr) 2021-03-25 2022-09-29 Iovance Biotherapeutics, Inc. Procédés et compositions pour dosages de puissance de coculture de lymphocytes t et utilisation avec des produits de thérapie cellulaire
TW202308669A (zh) 2021-04-19 2023-03-01 美商艾歐凡斯生物治療公司 嵌合共刺激性受體、趨化激素受體及彼等於細胞免疫治療之用途
JP2024526898A (ja) 2021-07-22 2024-07-19 アイオバンス バイオセラピューティクス，インコーポレイテッド 固形腫瘍断片の凍結保存のための方法
WO2023090774A1 (fr) * 2021-11-17 2023-05-25 의료법인 성광의료재단 Procédé amélioré de préparation d'un lymphocyte infiltrant les tumeurs
CN118401651A (zh) * 2022-01-29 2024-07-26 苏州沙砾生物科技有限公司 一种修饰的肿瘤浸润淋巴细胞及其用途
JP2025512313A (ja) 2022-04-06 2025-04-17 アイオバンス バイオセラピューティクス，インコーポレイテッド 腫瘍浸潤リンパ球療法によるｎｓｃｌｃ患者の治療
US20250281537A1 (en) 2022-05-10 2025-09-11 Iovance Biotherapeutics, Inc. Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with an il-15r agonist
EP4289939A1 (fr) * 2022-06-10 2023-12-13 Apeiron Biologics AG Population de cellules immunitaires transfectées et son procédé de production
EP4562131A2 (fr) * 2022-07-25 2025-06-04 Memorial Sloan Kettering Cancer Center Procédés de préparation pour thérapies cellulaires adoptives
US20260021181A1 (en) 2022-08-01 2026-01-22 Iovance Biotherapeutics, Inc. Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies
WO2024081791A2 (fr) * 2022-10-12 2024-04-18 The Brigham And Women's Hospital, Inc. Compositions et méthodes pour maintenir un programme d'interaction ccl3/ccl4 et ccr5 exprimé pendant la progression d'une tumeur
WO2024112571A2 (fr) 2022-11-21 2024-05-30 Iovance Biotherapeutics, Inc. Procédés bidimensionnels pour l'expansion de lymphocytes infiltrant les tumeurs et thérapies associées
WO2024118836A1 (fr) 2022-11-30 2024-06-06 Iovance Biotherapeutics, Inc. Procédés de production de lymphocytes infiltrant les tumeurs à étape rep raccourcie
CN117025530B (zh) * 2023-10-10 2023-12-12 再少年(北京)生物科技有限公司 用肿瘤坏死因子受体超家族激动剂扩增肿瘤浸润淋巴细胞（til）的方法

Family Cites Families (170)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
AU7873187A (en) 1986-08-08 1988-02-24 University Of Minnesota Method of culturing leukocytes
US6303121B1 (en) 1992-07-30 2001-10-16 Advanced Research And Technology Method of using human receptor protein 4-1BB
US6362325B1 (en) 1988-11-07 2002-03-26 Advanced Research And Technology Institute, Inc. Murine 4-1BB gene
US7479269B2 (en) 1988-11-23 2009-01-20 Genetics Institute, Llc Methods for selectively enriching TH1 and TH2 cells
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US6905680B2 (en) 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
US4902502A (en) 1989-01-23 1990-02-20 Cetus Corporation Preparation of a polymer/interleukin-2 conjugate
US5089261A (en) 1989-01-23 1992-02-18 Cetus Corporation Preparation of a polymer/interleukin-2 conjugate
ZA902710B (en) 1989-05-22 1991-12-24 Univ Georgia Res Found Enzyme luminescence assay
US5126132A (en) 1989-08-21 1992-06-30 The United States Of America As Represented By The Department Of Health And Human Services Tumor infiltrating lymphocytes as a treatment modality for human cancer
US5279833A (en) 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
AU7979491A (en) 1990-05-03 1991-11-27 Vical, Inc. Intracellular delivery of biologically active substances by means of self-assembling lipid complexes
EP0552178B1 (fr) 1990-10-12 1997-01-02 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Ribozymes modifies
ATE240394T1 (de) 1992-10-23 2003-05-15 Immunex Corp Methoden zur herstellung löslicher, oligomerer proteine
GB9317380D0 (en) 1993-08-20 1993-10-06 Therexsys Ltd Transfection process
US5821332A (en) 1993-11-03 1998-10-13 The Board Of Trustees Of The Leland Stanford Junior University Receptor on the surface of activated CD4+ T-cells: ACT-4
US6989434B1 (en) 1994-02-11 2006-01-24 Invitrogen Corporation Reagents for intracellular delivery of macromolecules
US5691188A (en) 1994-02-14 1997-11-25 American Cyanamid Company Transformed yeast cells expressing heterologous G-protein coupled receptor
US7175843B2 (en) 1994-06-03 2007-02-13 Genetics Institute, Llc Methods for selectively stimulating proliferation of T cells
EP0769063A1 (fr) 1994-06-27 1997-04-23 The Johns Hopkins University Systeme de transport de gene cible
US5908635A (en) 1994-08-05 1999-06-01 The United States Of America As Represented By The Department Of Health And Human Services Method for the liposomal delivery of nucleic acids
US5484720A (en) 1994-09-08 1996-01-16 Genentech, Inc. Methods for calcium phosphate transfection
US5830430A (en) 1995-02-21 1998-11-03 Imarx Pharmaceutical Corp. Cationic lipids and the use thereof
DK0766745T3 (da) 1995-04-08 2002-11-25 Lg Chemical Ltd Monoklonalt antistof, som er specifikt for humant 4-1BB samt cellelinje, som producerer dette
US5981501A (en) 1995-06-07 1999-11-09 Inex Pharmaceuticals Corp. Methods for encapsulating plasmids in lipid bilayers
US6010613A (en) 1995-12-08 2000-01-04 Cyto Pulse Sciences, Inc. Method of treating materials with pulsed electrical fields
US5849902A (en) 1996-09-26 1998-12-15 Oligos Etc. Inc. Three component chimeric antisense oligonucleotides
KR100520339B1 (ko) 1996-10-11 2005-10-12 브리스톨-마이어스스퀴브컴파니 면역조절 방법 및 조성물
US6248878B1 (en) 1996-12-24 2001-06-19 Ribozyme Pharmaceuticals, Inc. Nucleoside analogs
EP0973928B1 (fr) 1997-03-11 2010-05-05 Regents Of The University Of Minnesota Systeme transposon a base d'adn permettant d'introduire de l'acide nucleique dans l'adn d'une cellule
US6475994B2 (en) 1998-01-07 2002-11-05 Donald A. Tomalia Method and articles for transfection of genetic material
US6312700B1 (en) 1998-02-24 2001-11-06 Andrew D. Weinberg Method for enhancing an antigen specific immune response with OX-40L
AU6400600A (en) 1999-08-03 2001-02-19 Sequitur, Inc. Improvements in antisense oligomers, delivery of antisense oligomers, and identification of antisense oligomer targets
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US7189705B2 (en) 2000-04-20 2007-03-13 The University Of British Columbia Methods of enhancing SPLP-mediated transfection using endosomal membrane destabilizers
US6627442B1 (en) 2000-08-31 2003-09-30 Virxsys Corporation Methods for stable transduction of cells with hiv-derived viral vectors
WO2002036169A2 (fr) 2000-10-31 2002-05-10 Pr Pharmaceuticals, Inc. Methodes et compositions pour ameliorer l'administration de molecules bioactives
DE60317677T2 (de) 2002-06-13 2008-10-30 Crucell Holland B.V. Ox40 (=cd134) rezeptor agonisten und therapeutische verwendung
US20050084967A1 (en) 2002-06-28 2005-04-21 Xcyte Therapies, Inc. Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation
AU2003253684A1 (en) 2002-06-28 2004-01-19 Xcyte Therapies, Inc. Compositions and methods for restoring immune repertoire in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation
PL375144A1 (en) 2002-07-30 2005-11-28 Bristol-Myers Squibb Company Humanized antibodies against human 4-1bb
US7956176B2 (en) 2002-09-05 2011-06-07 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
AU2003265948B8 (en) 2002-09-06 2009-09-03 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Immunotherapy with in vitro-selected antigen-specific lymphocytes after nonmyeloablative lymphodepleting chemotherapy
ITMI20022118A1 (it) 2002-10-04 2004-04-05 Abiogen Pharma Spa Procedimento per la coltura su larga scala di t-linfociti in un sistema omogeneo.
US9228186B2 (en) 2002-11-14 2016-01-05 Thermo Fisher Scientific Inc. Methods and compositions for selecting siRNA of improved functionality
DK2284266T3 (da) 2002-11-14 2014-01-13 Thermo Fisher Scient Biosciences Inc sIRNA-MOLEKYLE MOD TP53
US10011836B2 (en) 2002-11-14 2018-07-03 Thermo Fisher Scientific Inc. Methods and compositions for selecting siRNA of improved functionality
US9839649B2 (en) 2002-11-14 2017-12-12 Thermo Fisher Scientific Inc. Methods and compositions for selecting siRNA of improved functionality
WO2006006948A2 (fr) 2002-11-14 2006-01-19 Dharmacon, Inc. Methodes et compositions permettant de selectionner des arnsi presentant une fonctionnalite amelioree
US9879266B2 (en) 2002-11-14 2018-01-30 Thermo Fisher Scientific Inc. Methods and compositions for selecting siRNA of improved functionality
US20040224405A1 (en) 2003-05-06 2004-11-11 Dharmacon Inc. siRNA induced systemic gene silencing in mammalian systems
EP3450538B1 (fr) 2003-10-08 2021-08-25 Wilson Wolf Manufacturing Corporation Procédés de culture cellulaire et dispositifs utilisant des matériaux perméables au gaz
US7288638B2 (en) 2003-10-10 2007-10-30 Bristol-Myers Squibb Company Fully human antibodies against human 4-1BB
EP1814568A4 (fr) 2004-10-29 2009-08-12 Univ Southern California Poly-immunotherapie anticancereuse dans laquelle sont utilisees des molecules co-stimulatrices
ES2605380T3 (es) 2005-05-06 2017-03-14 Providence Health & Services - Oregon Proteina de fusión OX40-inmunoglobulina trimérica y métodos de uso
CN103059138B (zh) 2005-05-09 2015-10-28 小野药品工业株式会社 程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法
WO2007005874A2 (fr) 2005-07-01 2007-01-11 Medarex, Inc. Anticorps monoclonaux humains diriges contre un ligand de mort programmee de type 1(pd-l1)
KR100650384B1 (ko) * 2005-09-12 2006-11-30 전남대학교산학협력단 성숙자연살해세포의 분화용 조성물 및 그 제조 방법
AU2006328945B2 (en) 2005-12-21 2011-06-30 Sentoclone International Ab Method for treating malignant melanoma
WO2007071388A1 (fr) 2005-12-21 2007-06-28 Sentoclone Ab Methode amelioree pour la proliferation de lymphocytes t reactifs a une tumeur a des fins d'immunotherapie pour des patients atteints de cancer
US8007785B2 (en) 2005-12-21 2011-08-30 Sentoclone International Ab Method for treating colon cancer with tumour-reactive T-lymphocytes
WO2007071389A1 (fr) 2005-12-21 2007-06-28 Sentoclone Ab Méthode de traitement de cancer disséminé
TWI466269B (zh) 2006-07-14 2014-12-21 Semiconductor Energy Lab 非揮發性記憶體
EP1894940A1 (fr) 2006-08-28 2008-03-05 Apogenix GmbH Protéines de fusion de la superfamille TNF
US8252755B2 (en) 2006-09-22 2012-08-28 Dharmacon, Inc. Duplex oligonucleotide complexes and methods for gene silencing by RNA interference
US8859229B2 (en) 2007-02-02 2014-10-14 Yale University Transient transfection with RNA
US9249423B2 (en) 2007-02-02 2016-02-02 Yale University Method of de-differentiating and re-differentiating somatic cells using RNA
BRPI0807269A2 (pt) 2007-02-27 2014-04-29 Genentech Inc "anticorpo antagonista isolado, molécula de ácido nucléico isolada, vetor, célula hospedeira, composição, método de tratamento, método para tratamento, método para reduzir a severidade da asma, método para produzir um anticorpo, hibridoma, uso do anitocrpo, método para detectar ox40, kits e aparelhos médicos"
US7951365B2 (en) 2007-06-27 2011-05-31 Deifiera Falun Ab Method for expansion of tumour-reactive T-lymphocytes for immunotherapy of patients with specific cancer types
EP3321277B1 (fr) 2007-07-10 2019-09-18 Apogenix AG Protéines de fusion collectines de la superfamille des tnf
US8541185B2 (en) 2007-09-24 2013-09-24 Technion Research & Development Foundation Limited Method of predicting responsiveness to autologous adoptive cell transfer therapy
US20090131360A1 (en) 2007-10-02 2009-05-21 Rxi Pharmaceuticals, Corp. Tripartite RNAi constructs
CA2707773C (fr) 2007-12-14 2017-01-10 Pfizer Inc. Liaison de molecules au recepteur humain ox40
WO2009102427A2 (fr) 2008-02-11 2009-08-20 Rxi Pharmaceuticals Corp. Polynucléotides d'arni modifiés et leurs utilisations
EP2540740B1 (fr) 2008-06-17 2014-09-10 Apogenix GmbH Récepteurs multimériques TNF
WO2010008582A2 (fr) 2008-07-18 2010-01-21 Rxi Pharmaceuticals Corporation Système permettant d'administrer un médicament aux cellules phagocytaires
JP5674155B2 (ja) 2008-07-21 2015-02-25 アポゲニクス ゲゼルシャフト ミット ベシュレンクテル ハフツングＡｐｏｇｅｎｉｘ ＧｍｂＨ Ｔｎｆｓｆ一本鎖分子
WO2010033248A2 (fr) 2008-09-22 2010-03-25 Rxi Pharmaceuticals Corporation Nanotransporteurs neutres
US8552154B2 (en) 2008-09-26 2013-10-08 Emory University Anti-PD-L1 antibodies and uses therefor
US8475790B2 (en) 2008-10-06 2013-07-02 Bristol-Myers Squibb Company Combination of CD137 antibody and CTLA-4 antibody for the treatment of proliferative diseases
US20150320798A1 (en) 2012-11-27 2015-11-12 The Johns Hopkins University Use of Post-Transplant Cyclophosphamide Treated Allogeneic Marrow Infiltrating Lymphocytes to Augment Anti-Tumor Immunity
WO2010078536A1 (fr) 2009-01-05 2010-07-08 Rxi Pharmaceuticals Corporation Inhibition de pcsk9 par arni
JP5844158B2 (ja) 2009-01-09 2016-01-13 アポゲニクス ゲゼルシャフト ミット ベシュレンクテル ハフツングＡｐｏｇｅｎｉｘ ＧｍｂＨ 三量体形成融合タンパク質
US9745574B2 (en) 2009-02-04 2017-08-29 Rxi Pharmaceuticals Corporation RNA duplexes with single stranded phosphorothioate nucleotide regions for additional functionality
US8383099B2 (en) * 2009-08-28 2013-02-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adoptive cell therapy with young T cells
US20110086869A1 (en) 2009-09-24 2011-04-14 The Trustees Of Boston University Methods for treating viral disorders
JP2013512694A (ja) 2009-12-08 2013-04-18 ウィルソン ウォルフ マニュファクチャリング コーポレイション 養子細胞療法のための細胞を培養する方法
US8956860B2 (en) 2009-12-08 2015-02-17 Juan F. Vera Methods of cell culture for adoptive cell therapy
US20130115617A1 (en) 2009-12-08 2013-05-09 John R. Wilson Methods of cell culture for adoptive cell therapy
WO2011109698A1 (fr) 2010-03-04 2011-09-09 Rxi Pharmaceuticals Corporation Formulations et procédés d'administration ciblée à des cellules phagocytaires
US9080171B2 (en) 2010-03-24 2015-07-14 RXi Parmaceuticals Corporation Reduced size self-delivering RNAi compounds
CN103200945B (zh) 2010-03-24 2016-07-06 雷克西制药公司 眼部症候中的rna干扰
KR101852210B1 (ko) 2010-03-24 2018-04-25 알엑스아이 파마슈티칼스 코포레이션 진피 및 섬유증성 적응증에서의 ｒｎａ 간섭
WO2013028231A1 (fr) 2011-08-23 2013-02-28 Board Of Regents, The University Of Texas System Anticorps anti-ox40 et leurs procédés d'utilisation
WO2012027328A2 (fr) 2010-08-23 2012-03-01 Board Of Regents, The University Of Texas System Anticorps anti-ox40 et leurs procédés d'utilisation
BR112013005699B1 (pt) 2010-09-09 2021-08-17 Pfizer Inc Anticorpo isolado ou porção de ligação ao antígeno do mesmo que se liga ao 4-1bb humano, combinação, usos dos mesmos, bem como composição farmacêutica, molécula de ácido nucleico isolada e vetor
US8962804B2 (en) 2010-10-08 2015-02-24 City Of Hope Meditopes and meditope-binding antibodies and uses thereof
HRP20210642T1 (hr) 2010-11-12 2021-05-28 Nektar Therapeutics Konjugati il-2 ostatka i polimera
US20120171295A1 (en) * 2010-12-30 2012-07-05 Sascha Abramson Methods for cryopreserving and encapsulating cells
WO2012129201A1 (fr) 2011-03-22 2012-09-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Procédés de mise en croissance de lymphocytes infiltrant une tumeur dans contenants perméables au gaz
CN103502439B (zh) 2011-04-13 2016-10-12 因缪尼卡姆股份公司 用于抗原特异性t细胞增殖的方法
WO2012177788A1 (fr) 2011-06-20 2012-12-27 La Jolla Institute For Allergy And Immunology Modulateurs de 4-1bb et réponses immunitaires
EA201490636A1 (ru) 2011-09-16 2014-08-29 Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания Сконструированные с помощью рнк t-клетки для лечения злокачественных новообразований
GB201116092D0 (en) 2011-09-16 2011-11-02 Bioceros B V Antibodies and uses thereof
HUE047507T2 (hu) 2011-10-17 2020-04-28 Massachusetts Inst Technology Intracelluláris célbajuttatás
JP5698421B2 (ja) 2011-10-21 2015-04-08 セル・メディカ・リミテッド 細胞の無菌増殖のための装置
GB201121308D0 (en) 2011-12-12 2012-01-25 Cell Medica Ltd Process
AU2013262485B2 (en) 2012-05-18 2017-12-14 Wilson Wolf Manufacturing, LLC Improved methods of cell culture for adoptive cell therapy
DK3473707T3 (da) 2012-05-25 2025-03-17 Cellectis Fremgangsmåder til engineering af allogen og immunsuppressiv resistent t-celle til immunoterapi
CN104411819B (zh) 2012-06-11 2019-05-10 威尔逊沃夫制造公司 用于过继细胞疗法的改进的细胞培养方法
ES2862433T3 (es) 2012-11-27 2021-10-07 Ivan Marques Borrello Uso de linfocitos infiltrantes de médula ósea alogénicos tratados con ciclofosfamida postrasplante para aumentar la inmunidad antitumoral
US8959044B2 (en) 2012-11-28 2015-02-17 Linkedin Corporation Recommender evaluation based on tokenized messages
ES2859678T3 (es) 2013-03-01 2021-10-04 Us Health Métodos para producir poblaciones enriquecidas de células T reactivas a tumores a partir de un tumor
AU2013379773B2 (en) 2013-03-01 2018-04-19 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Methods of producing enriched populations of tumor reactive T cells from peripheral blood
MD4633B1 (ro) 2013-03-18 2019-06-30 Biocerox Products B.V. Anticorpi umanizaţi anti-CD134 (OX40) şi utilizarea acestora
MX2015015638A (es) 2013-05-13 2016-10-28 Cellectis Metodos para diseñar celulas t altamente activas para inmunoterapia.
WO2014201021A2 (fr) * 2013-06-10 2014-12-18 Dana-Farber Cancer Institute, Inc. Procédés et compositions pour réduire l'immunodépression par des cellules tumorales
CN105392876B (zh) 2013-06-24 2019-07-23 威尔逊沃夫制造公司 用于透气性细胞培养过程的封闭系统装置和方法
EP3626817B1 (fr) 2013-07-15 2022-09-28 The United States of America, as represented by the Secretary, Department of Health and Human Services Procédés de préparation de lymphocytes t antigènes du papillomavirus humain
WO2015039100A1 (fr) 2013-09-16 2015-03-19 The Trustees Of The University Of Pennsylvania Enrichissement de cd137 pour la sélection de lymphocytes d'infiltration tumorale efficaces
WO2015084897A2 (fr) 2013-12-02 2015-06-11 Mirimmune, Llc Immunothérapie du cancer
WO2015095423A2 (fr) 2013-12-17 2015-06-25 Genentech, Inc. Polythérapie comprenant des agonistes se liant à ox40 et des antagonistes se liant à l'axe pd-1
TW201613635A (en) 2014-02-04 2016-04-16 Pfizer Combination of a PD-1 antagonist and a 4-1BB agonist for treating cancer
AU2015231041B2 (en) 2014-03-20 2020-07-16 H. Lee Moffitt Cancer Center And Research Institute, Inc. Tumor-infiltrating lymphocytes for adoptive cell therapy
EP3154350B1 (fr) * 2014-04-10 2024-03-27 H. Lee Moffitt Cancer Center And Research Institute, Inc. Expansion améliorée des lymphocytes infiltrants des tumeurs pour thérapie cellulaire adoptive
SG11201610350SA (en) 2014-06-11 2017-01-27 Polybiocept Ab Expansion of lymphocytes with a cytokine composition for active cellular immunotherapy
EP3155426B1 (fr) 2014-06-13 2023-07-19 Immudex ApS Détection générale et isolement de cellules spécifiques par liaison de molécules marquées
AU2015311761B2 (en) 2014-09-04 2020-11-12 The Johns Hopkins University Activation of marrow infiltrating lymphocytes in hypoxic alternating with normoxic conditions
EP4368205A1 (fr) 2014-09-16 2024-05-15 Innate Pharma Neutralisation de voies inhibitrices dans des lymphocytes
ES2924709T3 (es) 2014-10-02 2022-10-10 Us Health Métodos de aislamiento de receptores de células T que tienen especificidad antigénica para una mutación específica de cáncer
WO2016091744A1 (fr) * 2014-12-09 2016-06-16 Ge Healthcare Bio-Sciences Corp Systèmes et procédés de prélèvement aseptique
US12359197B2 (en) 2014-12-12 2025-07-15 Etagen Pharma, Inc. Compositions and methods for editing nucleic acids in cells utilizing oligonucleotides
EP3034092A1 (fr) 2014-12-17 2016-06-22 Université de Lausanne Immunothérapie adoptive pour traiter le cancer
US9944894B2 (en) 2015-01-16 2018-04-17 General Electric Company Pluripotent stem cell expansion and passage using a rocking platform bioreactor
EP3929293A3 (fr) 2015-04-03 2022-03-16 University Of Massachusetts Petit arn interférent asymétrique entièrement stabilisé
US10544392B2 (en) 2015-05-01 2020-01-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of isolating T cells and T cell receptors having antigenic specificity for a cancer-specific mutation from peripheral blood
FR3038324B1 (fr) 2015-06-30 2020-10-30 Lab Francais Du Fractionnement Procede de cryoconservation de cellules a visee therapeutique
FR3040396A1 (fr) 2015-06-30 2017-03-03 Chu Nantes Procede de cryoconservation de lymphocytes infiltrant la tumeur
SG10201912910PA (en) 2015-07-09 2020-02-27 Massachusetts Inst Technology Delivery of materials to anucleate cells
US10633653B2 (en) 2015-08-14 2020-04-28 University Of Massachusetts Bioactive conjugates for oligonucleotide delivery
EP3344575B1 (fr) 2015-09-04 2020-04-15 SQZ Biotechnologies Company Administration intracellulaire de biomolécules à des cellules comprenant une paroi cellulaire
WO2017048614A1 (fr) 2015-09-15 2017-03-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Procédés d'isolement de récepteurs de lymphocytes t réactifs à une tumeur à partir de tumeur ou de sang périphérique
JP2018531037A (ja) 2015-10-19 2018-10-25 アールエックスアイ ファーマシューティカルズ コーポレーション 長い非コードｒｎａを標的とする減少したサイズの自己送達型核酸化合物
CA3002745A1 (fr) 2015-10-22 2017-04-27 Juno Therapeutics Gmbh Procedes, kits et appareil de culture de cellules
US20190062706A1 (en) 2015-10-28 2019-02-28 Life Technologies As Selective expansion of different subpopulations of t cells by the alteration of cell surfacing signals and signal ratio
EP3397263B1 (fr) * 2015-12-30 2023-09-20 Celgene Corporation Procédés de production de lymphocytes t et lymphocytes t ainsi produits
EP4495222A3 (fr) 2016-01-12 2025-04-23 SQZ Biotechnologies Company Administration intracellulaire de complexes
US10478503B2 (en) 2016-01-31 2019-11-19 University Of Massachusetts Branched oligonucleotides
EP3452055A4 (fr) 2016-05-06 2019-11-06 Tod M. Woolf Procédés perfectionnés d'édition de génome avec et sans nucléases programmables
EP3248627B1 (fr) * 2016-05-27 2020-02-26 Fenwal, Inc. Systèmes et procédés d'amorçage d'un circuit de fluide
CN109310746B (zh) * 2016-06-24 2023-12-05 麦克马斯特大学 过继细胞转移与溶瘤病毒组合疗法
JP7034955B2 (ja) 2016-06-28 2022-03-14 ジーニアス・バイオテクノロジー・インコーポレイテッド 免疫療法向けのｔ細胞組成物
CN106244538A (zh) 2016-08-04 2016-12-21 英普乐孚生物技术(上海)有限公司 一种恶性腹水来源的til细胞的分离培养方法
HRP20201993T1 (hr) 2016-09-14 2021-02-05 Abbvie Biotherapeutics Inc. Protutijela protiv pd-1
FI3532607T3 (fi) 2016-10-26 2024-03-15 Iovance Biotherapeutics Inc Kryosäilytettyjen kasvaimiin infiltroituvien lymfosyyttien uudelleen stimulointi
TWI788307B (zh) 2016-10-31 2023-01-01 美商艾歐凡斯生物治療公司 用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
WO2018102761A1 (fr) 2016-12-02 2018-06-07 City Of Hope Procédés de préparation et d'accroissement de lymphocytes t exprimant des récepteurs antigéniques chimériques et d'autres récepteurs
CN106591232A (zh) 2017-01-04 2017-04-26 安徽安龙基因医学检验所有限公司 一种高效的pd‑1‑cd8+t细胞的培养方法
TWI902654B (zh) 2017-01-06 2025-11-01 美商艾歐凡斯生物治療公司 以腫瘤壞死因子受體超家族（ｔｎｆｒｓｆ）促效劑使腫瘤浸潤淋巴球（ｔｉｌ）擴增及ｔｉｌ與ｔｎｆｒｓｆ促效劑的治療組合
CN110913690A (zh) 2017-03-14 2020-03-24 朱诺治疗学股份有限公司 用于低温储存的方法
JOP20190224A1 (ar) 2017-03-29 2019-09-26 Iovance Biotherapeutics Inc عمليات من أجل إنتاج الخلايا اللمفاوية المرتشحة للأورام واستخداماتها في العلاج المناعي
MX2019013202A (es) 2017-05-10 2020-01-21 Iovance Biotherapeutics Inc Expansion de linfocitos de infiltracion de tumor a partir de tumores liquidos y usos terapeuticos de los mismos.
EP3635097A1 (fr) 2017-06-05 2020-04-15 Iovance Biotherapeutics, Inc. Procédés d'utilisation de lymphocytes infiltrant les tumeurs dans un mélanome doublement réfractaire
CN107384867B (zh) 2017-08-04 2020-09-11 北京世纪劲得生物技术有限公司 一种肿瘤组织til细胞制备方法及专用培养基

Also Published As

Publication number Publication date
CN117866899A (zh) 2024-04-12
CN111836887A (zh) 2020-10-27
US20220204932A1 (en) 2022-06-30
IL275724A (en) 2020-08-31
US12104172B2 (en) 2024-10-01
KR20200119242A (ko) 2020-10-19
AU2019205823C1 (en) 2026-01-08
JP2021509586A (ja) 2021-04-01
AU2025238034A1 (en) 2025-10-23
EP3737743A1 (fr) 2020-11-18
AU2019205823B2 (en) 2025-06-26
CA3087771A1 (fr) 2019-07-11
BR112020013848A2 (pt) 2020-12-01
MX2020007046A (es) 2020-09-07
SG11202006541UA (en) 2020-08-28
WO2019136456A1 (fr) 2019-07-11
TW201938177A (zh) 2019-10-01
AU2019205823A1 (en) 2020-07-30
JP2024015137A (ja) 2024-02-01

Similar Documents

Publication Publication Date Title
MA51636A (fr) Procédés de génération de produits de til enrichis pour des lymphocytes t spécifiques d'un antigène tumoral
MA40894A (fr) Immunoglobulines hétéro-dimères reciblant des lymphocytes t cd3/cd38 et leurs procédés de production
EP3335367A4 (fr) Système et procédés pour assurer l'intégrité de biens et d'une chaîne d'approvisionnement
EP3357673A4 (fr) Composition contenant une poudre métallique pour l'impression 3d, procédé d'impression 3d l'utilisant en tant que matière première et dispositif d'impression 3d
EP2839423A4 (fr) Systèmes et procédés pour fournir une promotion d'un produit combiné distribué à partir d'un distributeur de produits
EP3387800A4 (fr) Appareil et procédé d'utilisation d'une passerelle sécurisée de bord d'internet des objets
MA50859A (fr) Procédé pour la production d'une composition de lymphocytes t
EP3360961A4 (fr) Procédé de préparation de lymphocytes t génétiquement modifiés exprimant un récepteur antigénique chimérique
SA517381158B1 (ar) تفاعل إضافة مجموعة الكربوكسيل بتدفق مستمر
EP3813539A4 (fr) Procédés et dispositifs pour la production de biodiesel, d'hydrocarbures de type diesel, et produits obtenus à partir de ceux-ci
EP2935194A4 (fr) Systèmes et procédés pour obtenir des produits à partir d'une biomasse
MY184184A (en) Lysin glutamic acid dipeptide derivatives
EP3532090A4 (fr) Mutants d'endoglycosidase pour remodelage de glycoprotéine et leurs procédés d'utilisation
FR3018033B1 (fr) Dispositif de conditionnement d'une recharge d'un produit
EP3307758A4 (fr) Procédés et systèmes pour l'extraction de produits riches en protéines et hydrates de carbone à partir d'une microculture et compositions de ceux-ci
EP2861057A4 (fr) Appareil compact pour la production continue d'une substance produit à partir d'un matériau de départ cultivé en condition d'aquaculture
EP2945962A4 (fr) Procédés d'isolement de produits sanguins à partir d'une matière de produit sanguin appauvrie en protéine inter-alpha inhibiteur
MA46663A (fr) Systeme d'identification ou d'aide a l'identification d'un produit ou ensemble de produits
EP3414063A4 (fr) Appareils de tranchage et procédés pour trancher des produits
EP3484486A4 (fr) Composition pour produire de l'eau riche en hydrogène et d'autres produits
EP3413258A4 (fr) Plateforme de négociation d'objets basée sur une monnaie de commerce internationale
EP3830557A4 (fr) Appareil transporteur pour l'imagerie de produits alimentaires
FR3017030B1 (fr) Produit nutritionnel a base d'insectes
MA46968A (fr) Procédés d'induction de tolérance immunitaire à des facteurs de coagulation
EP3369426A4 (fr) Procédé pour augmenter la production de lymphocytes t cytotoxiques (ctl) spécifiques pour un antigène et d'anticorps